Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.

García-Bosch O, Gisbert JP, Cañas-Ventura A, Merino O, Cabriada JL, García-Sánchez V, Gutiérrez A, Nos P, Peñalva M, Hinojosa J, García-Planella E, Muñoz F, Calvet X, Panés J.

J Crohns Colitis. 2013 Oct;7(9):717-22. doi: 10.1016/j.crohns.2012.10.004. Epub 2012 Nov 8.

PMID:
23142005
2.

Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.

Subramaniam K, Richardson A, Dodd J, Platten J, Shadbolt B, Pavli P.

Intern Med J. 2014 May;44(5):464-70. doi: 10.1111/imj.12397.

PMID:
24612209
3.

Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis.

McDermott E, Murphy S, Keegan D, O'Donoghue D, Mulcahy H, Doherty G.

J Crohns Colitis. 2013 Mar;7(2):150-3. doi: 10.1016/j.crohns.2012.03.016. Epub 2012 Apr 18.

PMID:
22520592
4.

Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.

Ma C, Beilman CL, Huang VW, Fedorak DK, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

Can J Gastroenterol Hepatol. 2016;2016:2079582. doi: 10.1155/2016/2079582. Epub 2016 Jul 11.

5.

Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.

Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK.

J Crohns Colitis. 2014 Jul;8(7):571-81. doi: 10.1016/j.crohns.2014.01.010. Epub 2014 Feb 1. Review.

PMID:
24491514
6.

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.

Taxonera C, Estellés J, Fernández-Blanco I, Merino O, Marín-Jiménez I, Barreiro-de Acosta M, Saro C, García-Sánchez V, Gento E, Bastida G, Gisbert JP, Vera I, Martinez-Montiel P, Garcia-Morán S, Sánchez MC, Mendoza JL.

Aliment Pharmacol Ther. 2011 Feb;33(3):340-8. doi: 10.1111/j.1365-2036.2010.04531.x. Epub 2010 Dec 7.

7.

Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.

Christensen KR, Steenholdt C, Brynskov J.

Scand J Gastroenterol. 2015 Aug;50(8):1018-24. doi: 10.3109/00365521.2015.1019558. Epub 2015 Apr 10.

PMID:
25861832
8.

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.

Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

J Clin Gastroenterol. 2015 Sep;49(8):675-82. doi: 10.1097/MCG.0000000000000265.

PMID:
25389599
9.

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.

Baert F, Vande Casteele N, Tops S, Noman M, Van Assche G, Rutgeerts P, Gils A, Vermeire S, Ferrante M.

Aliment Pharmacol Ther. 2014 Dec;40(11-12):1324-32. doi: 10.1111/apt.12968. Epub 2014 Oct 2.

10.

Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.

Taxonera C, Iglesias E, Muñoz F, Calvo M, Barreiro-de Acosta M, Busquets D, Calvet X, Rodríguez A, Pajares R, Gisbert JP, López-Serrano P, Pérez-Calle JL, Ponferrada Á, De la Coba C, Bermejo F, Chaparro M, Olivares D, Alba C, Fernández-Blanco I.

Dig Dis Sci. 2017 Feb;62(2):481-490. doi: 10.1007/s10620-016-4398-5. Epub 2016 Dec 19.

PMID:
27995400
11.

Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.

Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A.

World J Gastroenterol. 2015 Mar 21;21(11):3282-90. doi: 10.3748/wjg.v21.i11.3282.

12.

Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.

Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L.

Inflamm Bowel Dis. 2013 Apr;19(5):1065-72. doi: 10.1097/MIB.0b013e3182802909.

PMID:
23448790
13.

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy.

Monterubbianesi R, Aratari A, Armuzzi A, Daperno M, Biancone L, Cappello M, Annese V, Riegler G, Orlando A, Viscido A, Meucci G, Gasbarrini A, Guidi L, Lavagna A, Sostegni R, Onali S, Papi C, Kohn A; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD).

J Crohns Colitis. 2014 Aug;8(8):852-8. doi: 10.1016/j.crohns.2014.01.006. Epub 2014 Jan 25.

PMID:
24472490
14.

The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.

Protic M, Seibold F, Schoepfer A, Radojicic Z, Juillerat P, Bojic D, Mwinyi J, Mottet C, Jojic N, Beglinger C, Vavricka S, Rogler G, Frei P.

J Crohns Colitis. 2014 Nov;8(11):1427-37. doi: 10.1016/j.crohns.2014.05.004. Epub 2014 Jun 5.

PMID:
24908178
15.

Adalimumab in active ulcerative colitis: a "real-life" observational study.

Italian Group for the Study of Inflammatory Bowel Disease, Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, Aratari A, Ardizzone S, Balestrieri P, Bossa F, Cappello M, Castiglione F, Cicala M, Danese S, D'Incà R, Dulbecco P, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Onali S, Orlando A, Papparella LG, Renna S, Ricci C, Rizzello F, Sostegni R, Guidi L, Papi C.

Dig Liver Dis. 2013 Sep;45(9):738-43. doi: 10.1016/j.dld.2013.03.018. Epub 2013 May 15.

PMID:
23683530
16.

Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.

Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J.

Gastroenterology. 2014 Jan;146(1):110-118.e3. doi: 10.1053/j.gastro.2013.09.032. Epub 2013 Sep 22.

PMID:
24067881
17.

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.

Lee KM, Jeen YT, Cho JY, Lee CK, Koo JS, Park DI, Im JP, Park SJ, Kim YS, Kim TO, Lee SH, Jang BI, Kim JW, Park YS, Kim ES, Choi CH, Kim HJ; IBD study Group of Korean Association for the Study of Intestinal Diseases.

J Gastroenterol Hepatol. 2013 Dec;28(12):1829-33. doi: 10.1111/jgh.12324.

PMID:
23829336
18.

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.

Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM.

World J Gastroenterol. 2016 Dec 21;22(47):10432-10439. doi: 10.3748/wjg.v22.i47.10432.

19.

Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.

Bálint A, Farkas K, Palatka K, Lakner L, Miheller P, Rácz I, Hegede G, Vincze Á, Horváth G, Szabó A, Nagy F, Szepes Z, Gábor Z, Zsigmond F, Zsóri Á, Juhász M, Csontos Á, Szűcs M, Bor R, Milassin Á, Rutka M, Molnár T.

J Crohns Colitis. 2016 Jan;10(1):26-30. doi: 10.1093/ecco-jcc/jjv169. Epub 2015 Sep 20.

PMID:
26392413
20.

Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.

Hussey M, Mc Garrigle R, Kennedy U, Holleran G, Kevans D, Ryan B, Breslin N, Mahmud N, McNamara D.

Eur J Gastroenterol Hepatol. 2016 Feb;28(2):217-21. doi: 10.1097/MEG.0000000000000515.

PMID:
26587866

Supplemental Content

Support Center